TS-065862 — The Need In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …

TS-065860 — The Need: Cancer remains one of the most pressing medical challenges of our time, demanding innovative solutions to enhance treatment efficacy while minimizing systemic toxicity. Conventional chemotherapy agents often suffer from poor solubility, instability, and indiscriminate cytotoxicity, necessi…

TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.

TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health

TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.

TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …

TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…

TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…

TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.

TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.

TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…

TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…

TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…

TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…

TS-064187 — The Need In the culinary and pharmaceutical realms, the need for a groundbreaking solution to modulate flavor and alleviate sensory perceptions is crucial. Businesses seek innovative ways to enhance consumer experiences by addressing pungency in foods and alleviating burn or pain sensations in phar…

TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.

TS-063433 — A new pharmacologic modality for treating AFib.

TS-063091 — A gene therapy approach to address the specific needs of failing hearts.